Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells

Zhang Q., Cao Z., Yan S., Chen B., Wu H., Cao H.

Narrative Review on Face & Skin, published in J Transl Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41107877
PMCID
PMC12535068
DOI
10.1186/s12967-025-07164-0
Citations
14

Abstract (original English)

Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is notorious for its aggressive nature and dismal prognosis, ranking as a leading cause of cancer-related mortality worldwide. Despite advancements in surgical techniques, chemotherapies, and novel therapeutic approaches, the overall survival rates remain bleak, primarily due to the complex and dynamic tumor microenvironment (TME) which fosters cancer progression and therapeutic resistance. Central to the TME are cancer-associated fibroblasts (CAFs), which exhibit significant heterogeneity and play multifaceted roles in tumor progression, ranging from remodeling the extracellular matrix to modulating immune responses. Recent breakthroughs in single-cell sequencing and spatial omics have unraveled the diverse functional states and spatial organization of various cell types within the TME, including distinct subtypes of CAFs which differ vastly in their influence on pancreatic cancer pathophysiology. This review delves into the intricate interactions between CAFs and pancreatic cancer cells, highlighting how metabolic reprogramming and immune regulation by CAFs contribute to the high malignancy of PDAC. By integrating single-cell and spatial resolution data, we offer new insights into the metabolic crosstalk and immune landscape remodeling driven by CAFs, establishing a foundation for targeting these stromal

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansCarcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor MicroenvironmentCancer-Associated Fibroblasts

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research